Novel vaccine technologies for the 21st century

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination

Nemes, E., Geldenhuys, H. D., Rozot, V., Rutkowski, K. T., Ratangee, F., Bilek, N., Mabwe, S., Makhethe, L., Erasmus, M., Toefy, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714021 · Cited by 653

Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis

Tait, D. R., Hatherill, M., Van Der Meeren, O., Ginsberg, A. M., Van Brakel, E., Salaun, B., Scriba, T. J., Akite, E. J., Ayles, H. M., Bollaerts, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909953 · Cited by 605

Prevention of tuberculosis in macaques after intravenous BCG immunization

Darrah, P. A., Zeppa, J. J., Maiello, P. A., Hackney, J. A., Wadsworth, M. H., Hughes, T. K., Pokkali, S., Swanson, P. A., Grant, N. L., Rodgers, M., et al. (2020) · Nature · doi:10.1038/s41586-019-1817-8 · Cited by 592

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454

Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus

Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E. A., Benhaim, M. A., Ravichandran, R., Carter, L. P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.046 · Cited by 444

A proof of concept for structure-based vaccine design targeting RSV in humans

Crank, M. C., Ruckwardt, T. J., Chen, M., Morabito, K. M., Phung, E., Costner, P. J., Holman, L. A., Hickman, S. P., Berkowitz, N. M., Gordon, I. J., et al. (2019) · Science · doi:10.1126/science.aav9033 · Cited by 333

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281

Designing Tomorrow's Vaccines

Nabel, G. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204186 · Cited by 271

Chasing Seasonal Influenza — The Need for a Universal Influenza Vaccine

Paules, C. I., Sullivan, S. G., Subbarao, K., & Fauci, A. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1714916 · Cited by 256

New Promise for Vaccines against Tuberculosis

Bloom, B. R. (2018) · New England Journal of Medicine · doi:10.1056/nejme1812483 · Cited by 27

A guide to vaccinology: from basic principles to new developments

Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593

mRNA-based therapeutics: powerful and versatile tools to combat diseases

Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852

A thermostable mRNA vaccine against COVID-19

Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 671

Lipids and Lipid Derivatives for RNA Delivery

Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 649

An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study

Yang, Z., Bogdan, P., & Nazarian, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-81749-9 · Cited by 271

mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications

Wang, Y., Kumari, M., Chen, G., Hong, M.-H., Yuan, J. P., Tsai, J.-L., & Wu, H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00977-5 · Cited by 198

Nanobiomaterial-based vaccination immunotherapy of cancer

Chen, F., Wang, Y., Gao, J., Saeed, M., Li, T., Wang, W., & Yu, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120709 · Cited by 159

Leveraging mRNA Sequences and Nanoparticles to Deliver SARS‐CoV‐2 Antigens In Vivo

Zeng, C., Hou, X., Yan, J., Zhang, C., Li, W., Zhao, W., Du, S., & Dong, Y. (2020) · Advanced Materials · doi:10.1002/adma.202004452 · Cited by 152

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

Aliprantis, A. O., Shaw, C. A., Griffin, P., Farinola, N., Railkar, R. A., Cao, X., Liu, W., Sachs, J. R., Swenson, C. J., Lee, H., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1829899 · Cited by 149

Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies

Hou, Y., Chen, M., Bian, Y., Hu, Y., Chuan, J., Zhong, L., Zhu, Y., & Tong, R. (2024) · npj Vaccines · doi:10.1038/s41541-024-00874-4 · Cited by 132

Phytochemical Engineered Bacterial Outer Membrane Vesicles for Photodynamic Effects Promoted Immunotherapy

Zhuang, W., Wang, Y., Yao, L., Zuo, L., Jiang, A., Wu, G., Nie, W., Huang, L., & Xie, H. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01280 · Cited by 103

An Integrated Polymeric mRNA Vaccine without Inflammation Side Effects for Cellular Immunity Mediated Cancer Therapy

Huang, P., Jiang, L., Pan, H., Ding, L., Zhou, B., Zhao, M., Zou, J., Li, B., Qi, M., Deng, H., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207471 · Cited by 96

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial

Chen, G.-L., Li, X.-F., Dai, X.-H., Li, N., Cheng, M.-L., Huang, Z., Shen, J., Ge, Y.-H., Shen, Z.-W., Deng, Y.-Q., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00280-9 · Cited by 82

Advanced technologies for the development of infectious disease vaccines

Gupta, A., Rudra, A., Reed, K., Langer, R., & Anderson, D. G. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01041-z · Cited by 87

Ionizable Lipid Nanoparticles for mRNA Delivery

Tang, X., Zhang, Y., & Han, X. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300006 · Cited by 76

Manganese nanodepot augments host immune response against coronavirus

Sun, Y., Yin, Y., Gong, L., Liang, Z., Zhu, C., Ren, C., Zheng, N., Zhang, Q., Liu, H., Liu, W. Y., et al. (2020) · Nano Research · doi:10.1007/s12274-020-3243-5 · Cited by 66

BCG vaccination strategies against tuberculosis: updates and perspectives

Qu, M., Zhou, X., & Li, H. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2007711 · Cited by 64

Recombinant vaccines in 2022: a perspective from the cell factory

Favaro, M. T. D. P., Atienza-Garriga, J., Martínez-Torró, C., Parladé, E., Vázquez, E., Corchero, J. L., Ferrer‐Miralles, N., & Villaverde, A. (2022) · Microbial Cell Factories · doi:10.1186/s12934-022-01929-8 · Cited by 64

BCG vaccination induces cross-protective immunity against pathogenic microorganisms

Soto, J. A., Gálvez, N. M. S., Andrade, C. A., Ramírez, M. A., Riedel, C. A., Kalergis, A. M., & Bueno, S. M. (2022) · Trends in Immunology · doi:10.1016/j.it.2021.12.006 · Cited by 54

Integrating Digital Health Solutions with Immunization Strategies: Improving Immunization Coverage and Monitoring in the Post-COVID-19 Era

Pavia, G., Branda, F., Ciccozzi, A., Romano, C., Locci, C., Azzena, I., Pascale, N., Marascio, N., Quirino, A., Matera, G., et al. (2024) · Vaccines · doi:10.3390/vaccines12080847 · Cited by 60

Rational development of a combined mRNA vaccine against COVID-19 and influenza

Ye, Q., Wu, M., Chao Hui, Z. H. O. U., Lu, X., Huang, B., Zhang, N., Zhao, H. J., Chi, H., Zhang, X., Ling, D., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00478-w · Cited by 51

Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery

Han, G., Noh, D., Lee, H., Lee, S., Kim, S., Yoon, H. Y., & Hyeon, L. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114973 · Cited by 53

COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy

Novelli, G., Biancolella, M., Mehrian‐Shai, R., Colona, V. L., Brito, A. F., Grubaugh, N. D., Vasiliou, V., Luzzatto, L., & Reichardt, J. K. V. (2021) · Human Genomics · doi:10.1186/s40246-021-00326-3 · Cited by 51

The Status and Prospects of Epstein–Barr Virus Prophylactic Vaccine Development

Sun, C., Chen, X., Kang, Y., & Zeng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.677027 · Cited by 52

Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines

Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 54

Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape

Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50

Messenger RNA chromatographic purification: advances and challenges

Xue, F., Su, Z. G., Cheng, Y., Ma, G., & Zhang, S. (2023) · Journal of Chromatography A · doi:10.1016/j.chroma.2023.464321 · Cited by 50

Nanotechnology in the Diagnosis and Treatment of Antibiotic-Resistant Infections

Ιωάννου, Π., Baliou, S., & Samonis, G. (2024) · Antibiotics · doi:10.3390/antibiotics13020121 · Cited by 50

Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine

Lopez, C. E., & Legge, K. L. (2020) · Vaccines · doi:10.3390/vaccines8030434 · Cited by 47

A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults

Shaw, C. A., August, A., Bart, S., Jackson-Booth, P.-G., Knightly, C., Brasel, T., Weaver, S. C., Zhou, H., & Panther, L. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.064 · Cited by 48

Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral Therapies and Vaccines

Jackman, J. A., Yoon, B. K., Ouyang, L., Wang, N., Ferhan, A. R., Kim, J., Majima, T., & Cho, N. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202008352 · Cited by 46

Dendritic Mesoporous Silica Nanoparticle Adjuvants Modified with Binuclear Aluminum Complex: Coordination Chemistry Dictates Adjuvanticity

Yang, Y., Tang, J., Song, H., Yang, Y., Gu, Z., Fu, J., Liu, Y., Zhang, M., Qiao, Z., & Yu, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006861 · Cited by 44

An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs

Li, J., Liu, Q., Liu, J., Wu, X., Lei, Y., Li, S., Zhao, D., Li, Z., Luo, L., Peng, S., et al. (2022) · Virology Journal · doi:10.1186/s12985-022-01919-7 · Cited by 46

Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration

Chan, L., Alizadeh, K., Alizadeh, K., Fazel, F., Kakish, J. E., Karimi, N., Knapp, J. P., Mehrani, Y., Minott, J. A., Morovati, S., et al. (2021) · Vaccines · doi:10.3390/vaccines9090979 · Cited by 40

A single subcutaneous or intranasal immunization with adenovirus‐based SARS‐CoV‐2 vaccine induces robust humoral and cellular immune responses in mice

Kim, E. R., Weisel, F. J., Balmert, S. C., Khan, M. S., Huang, S., Erdös, G., Kenniston, T. W., Carey, C. D., Joachim, S. M., Conter, L. J., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149167 · Cited by 40

The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants

Yadegari, I., Omidi, M., & Smith?, S. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-00083-2 · Cited by 29

Vaccination Strategies Based on Bacterial Self-Assembling Proteins as Antigen Delivery Nanoscaffolds

Lamontagne, F., Khatri, V., St‐Louis, P., Bourgault, S., & Archambault, D. (2022) · Vaccines · doi:10.3390/vaccines10111920 · Cited by 34

Nanoparticles and Antiviral Vaccines

Liu, S., Hu, M., Liu, X., Liu, X., Chen, T., Zhu, Y., Liang, T., Xiao, S., Li, P., & Ma, X. (2023) · Vaccines · doi:10.3390/vaccines12010030 · Cited by 35

Safe Polycationic Dendrimers as Potent Oral In Vivo Inhibitors of Mycobacterium tuberculosis : A New Therapy to Take Down Tuberculosis

Mignani, S. M., Tripathi, V. D., Soam, D., Tripathi, R. P., Das, S., Singh, S., Gandikota, R., Laurent, R., Karpus, A. O., Caminade, A., et al. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00355 · Cited by 32

Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses

Ou, B. S., Baillet, J., Interrante, M. V. F., Adamska, J., Zhou, X.-T., Saouaf, O. M., Yan, J., Klich, J., Jons, C., Meany, E. L., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn7187 · Cited by 24

Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivoPreprint

Zeng, C., Hou, X., Yan, J., Zhang, C., Li, W., Zhao, W., Du, S., & Dong, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.01.019877 · Cited by 29

Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer

Sanya, D. R. A., Cava, C., & Onésime, D. (2022) · Human Cell · doi:10.1007/s13577-022-00843-w · Cited by 26

A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade

Zhang, X., Tian, H., Chen, Y., Liang, B., Nice, E. C., Huang, C., Xie, N., & Zheng, S. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02836-3 · Cited by 25

Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques

Li, J., Yu, P., Liu, Q., Xu, L., Chen, Y., Li, Y., Zhang, F., Zhu, W., & Peng, Y. (2024) · npj Vaccines · doi:10.1038/s41541-024-00925-w · Cited by 24

Protein Expression Platforms and the Challenges of Viral Antigen Production

Sookhoo, J. R. V., Schiffman, Z., Ambagala, A. P. N., Kobasa, D., Pardee, K., & Babiuk, S. (2024) · Vaccines · doi:10.3390/vaccines12121344 · Cited by 24

Hyaluronic Acid-Glycine-Cholesterol Conjugate-Based Nanoemulsion as a Potent Vaccine Adjuvant for T Cell-Mediated Immunity

Lin, C.-A., Ho, H., Venkatesan, P., Huang, C., Cheng, Y.-J., Lin, Y.-H., Lin, H.-Y., Chen, T.-Y., Huang, M., & Lai, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101569 · Cited by 24

Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant

Cheong, Y., Kim, M., Ahn, J., Oh, H., Lim, J., Chae, W., Yang, S. W., Kim, M., Yu, J. E., Byun, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.769088 · Cited by 24

mRNA medicine: Recent progresses in chemical modification, design, and engineering

Hou, X., Shi, J., & Xiao, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6978-6 · Cited by 24

Older adults: panoramic view on the COVID-19 vaccination

Andryukov, B. G., & Besednova, N. N. (2021) · AIMS Public Health · doi:10.3934/publichealth.2021030 · Cited by 23

Living with HIV and Getting Vaccinated: A Narrative Review

VITO, A. D., Colpani, A., Trunfio, M., Fiore, V., Moi, G., Fois, M., Leoni, N., Ruiu, S., Babudieri, S., Calcagno, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11050896 · Cited by 21

The role of religiosity in product and technology acceptance: Evidence from COVID-19 vaccines

Orlandi, L. B., Febo, V., & Perdichizzi, S. (2022) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2022.122032 · Cited by 23

Innate and adaptive immune responses against Influenza A Virus: Immune evasion and vaccination strategies

Varghese, P. M., Kishore, U., & Rajkumari, R. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152279 · Cited by 19

Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems

de Moura, I. A., Silva, A. J. D., de Macêdo, L. S., Invenção, M. D. C. V., de Sousa, M. M. G., & de Freitas, A. C. (2022) · Pathogens · doi:10.3390/pathogens11121444 · Cited by 19

Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates

Collett, S., Earnest, L., Montoya, J. C., Edeling, M. A., Yap, A. H. Y., Wong, C. Y., Christiansen, D., Roberts, J., Mumford, J., Lecouturier, V., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1065609 · Cited by 19

Immunometabolism at the service of traditional Chinese medicine

Cui, H., Zhang, J., Cheng, X.-H., Zheng, J., Zhang, Q., Zheng, R., You, L., Han, D., & Shang, H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106081 · Cited by 18

Bacillus Calmette-Guérin (BCG) Revaccination and Protection Against Tuberculosis: A Systematic Review

Lawrence, A. (2024) · Cureus · doi:10.7759/cureus.56643 · Cited by 17

Recent advances in the influenza virus vaccine landscape: a comprehensive overview of technologies and trials

Clark, T. W., Tregoning, J. S., Fisher, H. R., Poletti, T., Amin, F., & Nguyen‐Van‐Tam, J. S. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00025-24 · Cited by 17

Advances in vaccines: revolutionizing disease prevention

Tripathi, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-38798-z · Cited by 17

A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age

Langley, J. M., Pastural, É., Halperin, S. A., McNeil, S., ElSherif, M. S., MacKinnon‐Cameron, D., Ye, L., Grange, C., Thibodeau, V., Cailhier, J., et al. (2020) · Vaccines · doi:10.3390/vaccines8030393 · Cited by 16

The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning?

Jhaveri, R. R. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.01.014 · Cited by 16

Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects

Li, X., Zhu, Y., Xue, Y., Chen, T., Sun, X., & Shi, H. (2025) · Cancers · doi:10.3390/cancers17121953 · Cited by 15

A DNA vaccine (EG95-PT1/2/3-IL2) encoding multi-epitope antigen and IL-2 provokes efficient and long-term immunity to echinococcosis

Zhao, Y., Bi, Q., Wei, Y., Wang, R., Wang, G., Fu, G., Ran, Z., Lu, J., Zhang, H., Zhang, L., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.047 · Cited by 15

The mRNA vaccine platform for veterinary species

Fazel, F., Doost, J. S., Raj, S., Boodhoo, N., Karimi, K., & Sharif, S. (2024) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2024.110803 · Cited by 19

Messenger RNA (mRNA) based therapeutics in transforming cardiovascular care: Progress, regulatory challenges and future perspectives

Khan, M., Musazzi, U. M., Manellari, S., Mouawad, N., Damiano, G., Rinaldi, R., Raucci, A., Costantino, S., Paneni, F., Minghetti, P., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107847 · Cited by 16

SSAPN: Spectral–Spatial Anomaly Perception Network for Unsupervised Vaccine Detection

Yin, A., Wang, Y., Chen, Y., Zeng, K., Zhang, H., & Mao, J. (2022) · IEEE Transactions on Industrial Informatics · doi:10.1109/tii.2022.3195168 · Cited by 14

Introduction: A Broad Perspective on the Concepts of Urban Dynamics, Environment, and Health

Sinha, B. R. K. (2023) · Springer eBooks · doi:10.1007/978-981-99-5744-6_1 · Cited by 14

Novel Lipid Nanoparticles Stable and Efficient for mRNA Transfection to Antigen-Presenting Cells

Choi, K. C., Lee, D. H., Lee, J., Lee, J. S., Lee, Y. K., Choi, M. J., Jeong, H. Y., Kim, M. W., Lee, C.-G., & Park, Y. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031388 · Cited by 14

Immune Responses to Respiratory Syncytial Virus Vaccines: Advances and Challenges

da Silva, G. S., Borges, S. G., Pozzebon, B. R., & de Souza, A. P. D. (2024) · Microorganisms · doi:10.3390/microorganisms12112305 · Cited by 14

Engineered Bionanomaterials for Precision Delivery of Nucleic Acid Drugs

Bian, X., Luo, Z., Peng, B., Chen, J., Lo, P. K., Zhou, L., & Wen, Y. (2025) · Small · doi:10.1002/smll.202502667 · Cited by 16

Optimizing rabies mRNA vaccine efficacy via RABV-G structural domain screening and heterologous prime-boost immunization

Li, D., Wang, X., Li, G., Zhou, J., Bian, L., Zhao, X., Xing, L., Zeng, J., Cui, J., Cui, L., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01098-w · Cited by 13

Development of prime–boost-type next-generation mucosal vaccines

Fujimoto, K., & Uematsu, S. (2019) · International Immunology · doi:10.1093/intimm/dxz085 · Cited by 13

Artificial Intelligence and Machine Learning Applications in Vaccine Development

Sarmadi, A., Hassanzadeganroudsari, M., & Soltani, M. B. (2023) · Wiley eBooks · doi:10.1002/9781119865728.ch11 · Cited by 16

Recent Advances in mRNA Delivery Systems for Cancer Therapy

Zhang, Z., Fan, Y., Jiang, S., Ma, Y., Yu, Y., Qing, Y., Li, Q., Liu, Y., Shen, S., & Wang, J. (2025) · Advanced Science · doi:10.1002/advs.202417571 · Cited by 17

The Race for a COVID-19 Vaccine: Current Trials, Novel Technologies, and Future Directions

Brown, S., Brown, T., Cederna, P. S., & Rohrich, R. J. (2020) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000003206 · Cited by 14

Selective Plate-Based Assay for Trace EDTA Analysis via Boron Trifluoride-methanol Derivatization UHPLC-QqQ-MS/MS Enabling Biologic and Vaccine Processes

Bennett, R., Cohen, R. D., Wang, H., Pereira, T., Haverick, M. A., Loughney, J. W., Barbacci, D. C., Pristatsky, P., Bowman, A. M., Losacco, G. L., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04224 · Cited by 10

Construction and protective efficacy of a novel Streptococcus pneumoniae fusion protein vaccine NanAT1-TufT1-PlyD4

Cui, Y., Miao, C., Chen, W., Shang, W., Qi, Q., Zhou, W. L., Wang, X., Li, Y., Yan, Z., & Jiang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1043293 · Cited by 12

Examining the cooperativity mode of antibody and CD8+ T cell immune responses for vaccinology

Bocharov, G. A., Grebennikov, D. S., Argilaguet, J. M., & Meyerhans, A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.08.003 · Cited by 11

COVID-19 vaccination challenges: A mini-review

Afshar, Z. M., Barary, M., Hosseinzadeh, R., Karim, B., Ebrahimpour, S., Nazary, K., Sio, T. T. W., Sullman, M. J. M., Carson‐Chahhoud, K., Moudi, E., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2066425 · Cited by 14

Immunogenicity and protective efficacy of Ag85A and truncation of PstS1 fusion protein vaccines against tuberculosis

Zeng, L., Ma, X., Qu, M., Tang, M., Li, H., Lei, C., Ji, J., & Li, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27034 · Cited by 10

Sparsely PEGylated poly(beta-amino ester) polyplexes enhance antigen specific T-cell response of a bivalent SARS-CoV-2 DNA vaccine

Bayraktutan, H., Symonds, P., Brentville, V. A., Moloney, C., Galley, C., Bennett, C. L., Mata, Á., Durrant, L. G., Alexander, C., & Gurnani, P. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122647 · Cited by 10

DNA‐Engineered Modular Nanovaccines Featuring Precise Topology for Enhanced Immunogenicity

Qu, Y., Wang, D., Zhang, Y., Shen, F., Xia, B., Xu, Q. L., Wang, Q., Kong, H., Zhu, Y., Wang, L., et al. (2025) · Advanced Materials · doi:10.1002/adma.202500577 · Cited by 9

Leaf Saponins of Quillaja brasiliensis as Powerful Vaccine Adjuvants

Morais, V., Suárez, N., Cibulski, S. P., & Silveira, F. L. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17080966 · Cited by 10

Highly scalable prefusion-stabilized RSV F vaccine with enhanced immunogenicity and robust protection

Huang, Q.-L., Lang, Q., Li, Y., Wang, F., Han, X., Luo, L., Duan, X., Cao, X., Wang, Y., Bai, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63084-z · Cited by 10

virusMED: an atlas of hotspots of viral proteins

Zhang, H., Chen, P., Ma, H., Woińska, M., Liu, D., Cooper, D. R., Peng, G., Peng, Y., Deng, L., Minor, W., et al. (2021) · IUCrJ · doi:10.1107/s2052252521009076 · Cited by 9

Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine

McAndrew, T., Cambeiro, J., & Besiroglu, T. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.054 · Cited by 10

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

Myers, M. L., Gallagher, J. R., Woolfork, D. D., Stradtmann-Carvalho, R. K., Maldonado-Puga, S., Bock, K. W., Boyoglu-Barnum, S., Syeda, H., Creanga, A., Alves, D. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1002286 · Cited by 9

Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection

Lopez, C. E., Zacharias, Z. R., Ross, K. A., Narasimhan, B., Waldschmidt, T. J., & Legge, K. L. (2024) · npj Vaccines · doi:10.1038/s41541-024-00883-3 · Cited by 9

Enhancing explainable SARS-CoV-2 vaccine development leveraging bee colony optimised Bi-LSTM, Bi-GRU models and bioinformatic analysis

Ozsahin, D. U., Ameen, Z. S., Hassan, A. S., & Mubarak, A. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-55762-7 · Cited by 8

Against Clostridioides difficile Infection: An Update on Vaccine Development

Wang, J., Ma, Q., & Tian, S. (2025) · Toxins · doi:10.3390/toxins17050222 · Cited by 9

Simultaneous Immunization with Multiple Diverse Immunogens Alters Development of Antigen-Specific Antibody-Mediated Immunity

Pilewski, K. A., Kramer, K. J., & Georgiev, I. S. (2021) · Vaccines · doi:10.3390/vaccines9090964 · Cited by 8

Hepatitis E vaccines: A mini review

Ahmad, T., Haroon, H., Ahmad, K., Shah, S. M., Shah, M. W., Shah, S. M., Hussain, A., Jalal, S., Ahmad, W., Khan, M. A., et al. (2021) · Biomedical Research and Therapy · doi:10.15419/bmrat.v8i9.690 · Cited by 8

Implementation of immuno-chemoinformatics approaches to construct multi-epitope for vaccine development against Omicron and Delta SARS-CoV-2 variants

Dawood, A. A. (2022) · Vacunas · doi:10.1016/j.vacun.2022.05.006 · Cited by 11

Vaccination in pregnancy

Nassar, A. H., Hobeika, E. M., Chamsy, D. J., El‐Kak, F., & Usta, I. M. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14876 · Cited by 10

Vaccine therapy for dysbiosis-related diseases

Fujimoto, K., & Uematsu, S. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i21.2758 · Cited by 9

Trained Immunity-Based Vaccines: A Ready-to-Act Strategy to Tackle Viral Outbreaks

Conejero, L., Saz-Leal, P., & Subiza, J. L. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.95765 · Cited by 9

Developing STEM students’ worksheet to improve students' creative thinking ability

Pasaribu, K., Khairuna, K., Adlini, M. N., & Abrori, F. M. (2023) · Research and Development in Education (RaDEn) · doi:10.22219/raden.v3i2.25331 · Cited by 12

Nucleic Acids for Potential Treatment of Rheumatoid Arthritis

Sun, P., Su, J., Wang, X., Zhou, M., Zhao, Y., & Gu, H. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01205 · Cited by 8

Vaccine Production, Safety, and Efficacy

Brouwers, T. J., & van der Zeijst, B. A. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814515-9.00121-1 · Cited by 8

Recent advances on vaccines against malaria: A review

Malik, S., & Waheed, Y. (2024) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/apjtm.apjtm_678_23 · Cited by 8

A Review on Novel Approaches in Vaccine Development

Shaikh Mujeeb Ur Rahman, A. Q. Q. *. (2025) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.15779378

Contemporary vaccine approaches and role of next-generation vaccine adjuvants in managing viral diseases

Saxena, S. K., Maurya, V. K., Kumar, S., & Bhatt, M. L. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816352-8.00018-7

Advances in the structure-based design of protein vaccines for respiratory infectious diseases

Tie, X., Li, J., Wu, H., Weng, R., Zhang, Y., Li, J., & Chen, K. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.10.008 · Cited by 5

Structural vaccinology expedites rational design of next-generation vaccines for influenza and respiratory syncytial virus

Deng, L., Liu, J., & Peng, Y. (2026) · Virologica Sinica · doi:10.1016/j.virs.2026.03.011

Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections

Elkashif, A., Alhashimi, M., Sayedahmed, E. E., Sambhara, S. R., & Mittal, S. K. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1345 · Cited by 41